参考文献/References:
[1] Zheng R,Zhao H,An L,et al.Incidence and survival of neuroendocrine neoplasms in China with comparison to the United States[J].Chin Med J(Engl),2023,136:1216-1224.
[2]Rindi G,Mete O,Uccella S,et al.Overview of the 2022 WHO classification of neuroendocrine neoplasms[J].Endocr Pathol,2022,33:115-154.
[3]马建兵,杨朝爱,江 旭,等.TACE治疗胰腺神经内分泌肿瘤肝转移的疗效分析[J].介入放射学杂志,2019,28:468-471.
[4]Concors SJ,Maxwell JE.Neuroendocrine hepatic metastatic disease:the surgeon's perspective[J].Abdom Radiol(NY),2022,47:4073-4080.
[5]Pavel M,O'Toole D,Costa F,et al.ENETS consensus guidelines update for the management of distant metastatic disease of intestinal,pancreatic,bronchial neuroendocrine neoplasms(NEN)and NEN of unknown primary site[J].Neuroendocrinology,2016,103:172-185.
[6]Pavel M,Oberg K,Falconi M,et al.Gastroenteropancreatic neuroendocrine neoplasms:ESMO Clinical Practice Guidelines for diagnosis,treatment and follow-up[J].Ann Oncol,2020,31:844-860.
[7]NCCN.The NCCN Clinical Practice Guidelines in Oncology-Neuroendocrine and Adrenal Tumors(2023 Version1)[EB/OL].http://www.nccn.org 2023-08-02 108-109.
[8]中国抗癌协会神经内分泌肿瘤专业委员会.中国抗癌协会神经内分泌肿瘤诊治指南(2022年版)[J].中国癌症杂志,2022,32:545-580.
[9]中国临床肿瘤学会神经内分泌肿瘤专家委员会.中国胃肠胰神经内分泌肿瘤专家共识(2022年版)[J].中华肿瘤杂志,2022,44:1305-1329.
[10]Zener R,Yoon H,Ziv E,et al.Outcomes after transarterial embolization of neuroendocrine tumor liver metastases using spherical particles of different sizes[J].Cardiovasc Intervent Radiol,2019,42:569-576.
[11]Chen JX,Rose S,White SB,et al.Embolotherapy for neuroendocrine tumor liver metastases:prognostic factors for hepatic progression-free survival and overall survival[J].Cardiovasc Intervent Radiol,2017,40:69-80.
[12]Bhagat N,Reyes DK,Lin MD,et al.Phase Ⅱ study of chemoembolization with drug-eluting beads in patients with hepatic neuroendocrine metastases:high incidence of biliary injury[J].Cardiovasc Intervent Radiol,2013,36:449-459.
[13]Tamura M,Nakatsuka S,Torikai H,et al.Portal vein damage after DEB-TACE and Lipiodol-TACE:based on evaluation by computed tomography during arterial portography[J].Interv Radiol(Higashimatsuyama),2021,6:93-101.
[14]Guiu B,Deschamps F,Aho S,et al.Liver/biliary injuries following chemoembolisation of endocrine tumours and hepatocellular carcinoma:lipiodol vs.drug-eluting beads[J].J Hepatol,2012,56:609-617.
[15]张 超,李 非,李 昂,等.肝动脉化疗栓塞治疗原发病灶切除的胰腺神经内分泌肿瘤肝转移疗效分析[J].介入放射学杂志,2020,29:772-776.
[16]Marrache F,Vullierme MP,Roy C,et al.Arterial phase enhancement and body mass index are predictors of response to chemoembolisation for liver metastases of endocrine tumours[J].Br J Cancer,2007,96:49-55.
[17]Pericleous M,Caplin ME,Tsochatzis E,et al.Hepatic artery embolization in advanced neuroendocrine tumors:efficacy and long-term outcomes[J].Asia Pac J Clin Oncol,2016,12:61-69.
[18]Kanabar R,Barriuso J,McNamara MG,et al.Liver embolisation for patients with neuroendocrine neoplasms:systematic review[J].Neuroendocrinology,2021,111:354-369.
[19]刘海宽,陈文川,刘一铭,等.肝动脉栓塞术治疗42例低-中级别乏血供型神经内分泌肿瘤肝转移的近期疗效及安全性分析[J].中华介入放射学电子杂志,2020,8:130-134.
[20]Fiore F,Del Prete M,Franco R,et al.Transarterial embolization(TAE)is equally effective and slightly safer than transarterial chemoembolization(TACE)to manage liver metastases in neuroendocrine tumors[J].Endocrine,2014,47:177-182.
[21]de Baere T,Deschamps F,Tselikas L,et al.GEP-NETS update:Interventional radiology:role in the treatment of liver metastases from GEP-NETs[J].Eur J Endocrinol,2015,172:R151-R166.
[22]Ebbers SC,van Roekel C,Braat MNGJA,et al.Dose-response relationship after yttrium-90-radioembolization with glass microspheres in patients with neuroendocrine tumor liver metastases[J].Eur J Nucl Med Mol Imaging,2022,49:1700-1710.
[23]Schaarschmidt BM,Wildgruber M,Kloeckner R,et al.90Y radioembolization in the treatment of neuroendocrine neoplasms:results of an international multicenter retrospective study[J].J Nucl Med,2021:262561.
[24]de Mestier L,Zappa M,Hentic O,et al.Liver transarterial embolizations in metastatic neuroendocrine tumors[J].Rev Endocr Metab Disord,2017,18:459-471.
[25]Tomozawa Y,Jahangiri Y,Pathak P,et al.Long-term toxicity after transarterial radioembolization with yttrium-90 using resin microspheres for neuroendocrine tumor liver metastases[J].J Vasc Interv Radiol,2018,29:858-865.
[26]Su YK,Mackey RV,Riaz A,et al.Long-term hepatotoxicity of yttrium-90 radioembolization as treatment of metastatic neuroendocrine tumor to the liver[J].J Vasc Interv Radiol,2017,28:1520-1526.
[27]Currie BM,Nadolski G,Soulen MC.Response letter to correspondence regarding "chronic hepatotoxicity in patients with metastatic neuroendocrine tumor:transarterial chemoembolization versus transarterial radioembolization"[J].J Vasc Interv Radiol,2021,32:483-484.
[28]Clift AK,Frilling A.Liver-directed therapies for neuroendocrine neoplasms[J].Curr Oncol Rep,2021,23:44.
[29]刘一铭,连 帆,周翔飞,等.肝动脉栓塞术联合长效奥曲肽降低中低级别神经内分泌瘤肝转移负荷的疗效及安全性分析[J].中华医学杂志,2019,99:1142-1146.
[30]Liu Y,Liu H,Chen W,et al.Prolonged progression-free survival achieved by octreotide LAR plus transarterial embolization in low-to-intermediate grade neuroendocrine tumor liver metastases with high hepatic tumor burden[J].Cancer Med,2022,11:2588-2600.
[31]张 扬,徐瑞彤,柏建安,等.肝动脉栓塞术治疗神经内分泌肿瘤肝转移患者的疗效、预后和影响因素分析[J].中华医学杂志,2023,103:2952-2958.
[32]Ranieri G,Ammendola M,Marech I,et al.Vascular endothelial growth factor and tryptase changes after chemoembolization in hepatocarcinoma patients[J].World J Gastroenterol,2015,21:6018-6025.
[33]秦焕蓉,程芝梅,吴祥锴,等.经导管动脉化疗栓塞和微波消融治疗VX2肝癌诱导低氧诱导因子-1α调节糖酵解与微血管密度相关性分析研究[J].介入放射学杂志,2024,33:390-396.
[34]Strosberg JR,Weber JM,Choi J,et al.A phase Ⅱ clinical trial of sunitinib following hepatic transarterial embolization for metastatic neuroendocrine tumors[J].Ann Oncol,2012,23:2335-2341.
[35]Hu H,Chen Y,Tan S,et al.The research progress of antiangiogenic therapy,immune therapy and tumor microenvironment[J].Front Immunol,2022,13:802846.
[36]Halperin DM,Liu S,Dasari A,et al.Assessment of clinical response following atezolizumab and bevacizumab treatment in patients with neuroendocrine tumors:a nonrandomized clinical trial[J].JAMA Oncol,2022,8:904-909.
[37]Tamburini J,Chapuis N,Bardet V,et al.Mammalian target of rapamycin(mTOR)inhibition activates phosphatidylinositol 3-kinase/Akt by up-regulating insulin-like growth factor-1 receptor signaling in acute myeloid leukemia:rationale for therapeutic inhibition of both pathways[J].Blood,2008,111:379-382.
[38]Walter T,Lepage C,Coriat R,et al.Everolimus after hepatic arterial embolisation therapy of metastases from gastrointestinal neuroendocrine tumours:The FFCD 1104-EVACEL-GTE phase Ⅱ study[J].Eur J Cancer,2019,123:92-100.
[39]Kim HS,Shaib WL,Zhang C,et al.Phase 1b study of pasireotide,everolimus,and selective internal radioembolization therapy for unresectable neuroendocrine tumors with hepatic metastases[J].Cancer,2018,124:1992-2000.
[40]Braat AJAT,Bruijnen RCG,van Rooij R,et al.Additional holmium-166 radioembolisation after lutetium-177-dotatate in patients with neuroendocrine tumour liver metastases(HEPAR PLuS):a single-centre,single-arm,open-label,phase 2 study[J].Lancet Oncol,2020,21:561-570.
[41]Braat AJAT,Kappadath SC,Ahmadzadehfar H,et al.Radioembolization with 90Y resin microspheres of neuroendocrine liver metastases:International multicenter study on efficacy and toxicity[J].Cardiovasc Intervent Radiol,2019,42:413-425.
[42]Ezziddin S,Meyer C,Kahancova S,et al.90Y radioembolization after radiation exposure from peptide receptor radionuclide therapy[J].J Nucl Med,2012,53:1663-1669.
[43]Soulen MC,Teitelbaum UR,Mick R,et al.Integrated capecitabine-temozolomide with radioembolization for liver-dominant G2 NETs:long-term outcomes of a single-institution retrospective study[J].Cardiovasc Intervent Radiol,2024,47:60-68.
(收稿日期:2024-04-16)
(本文编辑:谷 珂)
相似文献/References:
[1]李晓光,金征宇,潘杰,等.肝动脉化疗或栓塞治疗胰腺神经内分泌肿瘤肝转移的疗效分析[J].介入放射学杂志,2010,(06):442.
LI Xiaoguang,JIN Zhengyu,PAN Jie,et al.Hepatic transarterial chemoperfusion and chemoembolization for the treatment of liver metastases from pancreatic neuroendocrine tumors：a therapeutic analysis[J].J Intervent Med,2010,(05):442.
[2]李伟.肝脏恶性肿瘤的化学栓塞治疗[J].介入放射学杂志,1998,(01):21.
[3]曾国斌,张开鄂.胰腺癌肝转移药盒植入置管方法改良一例报告[J].介入放射学杂志,1998,(02):70.
[4]高中度,茅爱武,朱元禄,等.大肠癌肝转移的介入治疗[J].介入放射学杂志,1999,(02):30.
[5]方心华,王淦森.应用国产XG500毫安X线机开展肿瘤介入性治疗的体会[J].介入放射学杂志,1993,(01):38.
[6]戴秋根.内脏倒置直肠癌肝转移动脉化疗一例[J].介入放射学杂志,1995,(02):69.
[7]谢其康,李焕祥,张西,等.动脉灌注化疗对有无肝转移的进展期胃癌疗效的比较[J].介入放射学杂志,1995,(03):144.
[8]张亮,范卫君,顾仰葵,等.鼻咽癌肝转移的综合介入治疗[J].介入放射学杂志,2006,(01):20.
ZHANG Liang,FAN Wei-jun,GU Yang-kui,et al.A comprehensive interventional therapy for liver metastasis caused by nasopharyngeal carcinoma[J].J Intervent Med,2006,(05):20.
[9]范卫君,张亮,顾仰葵,等.大肠癌肝转移的射频消融治疗[J].介入放射学杂志,2006,(02):75.
FAN Wei-jun,ZHANG Liang,GU Yang-kui,et al.Percutaneous radiofrequency ablation in the treatment of liver metastasis caused by colorectal cancer[J].J Intervent Med,2006,(05):75.
[10]陆 进,王卫东,徐 平,等.胃癌肝转移的治疗方法探讨与疗效比较[J].介入放射学杂志,2010,(10):814.
LU Jin,WANG Wei-dong,XU Pin,et al.Investigation of the therapeutic regimes for liver metastasis from gastric cancer and analysis of therapeutic effects[J].J Intervent Med,2010,(05):814.